Drug Type AAV based gene therapy |
Synonyms adeno-associated virus serotype 9 vector-delivered SMN1 gene therapy (Genzyme/University of California San Francisco/Emory University/Georgetown University) |
Target |
Action stimulants |
Mechanism SMN1 gene stimulants(survival of motor neuron 1, telomeric gene stimulants) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Spinal Muscular Atrophy | Discovery | United States | - | |
Spinal Muscular Atrophy | Discovery | United States | - | |
Spinal Muscular Atrophy | Discovery | United States | - | |
Spinal Muscular Atrophy | Discovery | United States | - |